Kuwait leads the way in protecting children through latest RSV treatment

• Kuwait is the first country in Middle East to offer Nirsevimab as an optional treatment for all newborns in respiratory diseases.

• Kuwait is committed to stay abreast in combating the Respiratory Syncytial Virus (RSV).

As part of Kuwait’s commitment to children’s health, the Ministry of Health announced the provision of ‘Nirsevimab’ a new generation antibody against the ‘Respiratory Syncytial Virus (RSV)’ to protect against acute respiratory diseases like Bronchitis and Pneumonia.

The Nirsevimab drug is characterized by long-term effectiveness and high efficiency, providing necessary protection with just one dose, representing a significant advancement in health prevention.

Symptoms and Causes of RSV:

In this context, The Chairman of the Council of Departments of Children and Premature Children and a member of the National Committee for Immunization, Dr. Wafaa Al-Ateeqi, explained that the Respiratory Syncytial Virus (RSV) is one of the most common viruses affecting the respiratory system, causing inflammation of the lungs and airways.

The RSV is often more active during the winter and primarily affects infants and children under two years of age, with two out of every three children being affected.

Dr. Al-Ateeqi highlighted that the symptoms of RSV infection often resemble those of a common cold, including a runny nose, cough, and a slight fever. However, the condition can quickly worsen, leading to difficulty in breathing, an increased breathing rate, and noticeable wheezing.

On a cautionary note, Dr. Al-Ateeqi added that infants, and children under two years of age, may suffer from severe respiratory complications that require hospital treatment.

Dr. Al-Ateeqi emphasized that international health organizations, including the US Center for Disease Control (CDC), recommend administering Nirsevimab to infants and children under two at risk.

The drug has been shown to reduce RSV incidence and hospitalization by approximately 90%, and it is included in immunization programs in many developed countries.

To conclude, Dr. Al-Ateeqi stated that Kuwait is the first country in the Middle East to offer Nirsevimab as an optional treatment for all newborns, reflecting the country’s commitment to staying at the forefront of scientific advancements in combating major causes of acute respiratory diseases like Bronchitis and Pneumonia.